Walter Rayford

National Institutes of Health

Papers

1

Total Citations

114

H-Index

1

About

Walter Rayford is a leading figure in urologic oncology, with a research focus on the early detection and discrimination of prostate cancer using advanced proteomic technologies. His most cited work, a seminal 2004 study, demonstrated that serum proteomic profiling, combined with artificial intelligence pattern recognition algorithms, could reliably distinguish prostate cancer from benign prostatic conditions in men with total PSA levels between 2.5 and 15.0 ng/mL. This breakthrough addressed a critical clinical challenge—reducing unnecessary biopsies while improving cancer detection accuracy. With over 114 citations, this paper has influenced the integration of machine learning into cancer diagnostics. Rayford’s contributions extend to the development of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) as a tool for analyzing complex serum data streams, paving the way for non-invasive, biomarker-driven screening. His work remains a cornerstone for researchers exploring precision oncology and computational pathology, underscoring his impact on both translational science and clinical decision-making in prostate cancer management.

Research Focus

Key Achievements

1
H-Index
1
Papers
114
Total Citations
114
Avg Citations/Paper
🏆 Most Cited Paper
SERUM PROTEOMIC PROFILING CAN DISCRIMINATE PROSTATE CANCER FROM BENIGN PROSTATES IN MEN WITH TOTAL PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2.5 AND 15.0 NG/ML
114 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: National Institutes of Health

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago